ArticleJCO oncology practice2026
Comparing Trends in Telemedicine Use and Geographic Disparities in Utilization Among Patients With Cancer in the United States.
Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeStudies have shown that rural populations were less likely than urban populations to use telemedicine during and after the COVID-19 pandemic. These trends are not well characterized nationally for patients with cancer.
methodsThis cohort analysis, using 2 years of Medicare fee-for-service claims (2020-2021), identified patients with incident or prevalent lung or colon cancer in 2020. Rurality of patient residence was classified using rural-urban commuting area codes as metropolitan, micropolitan, or small town/rural. We used generalized estimating equations to model outpatient (telemedicine and in-person) visit trends in 2020 and 2021 by rurality, adjusting for local COVID-19 rates, US region, and clinical and demographic factors.
resultsWe identified 355,868 patients (66% lung, 34% colon). Median age was 76 years (standard deviation [SD], 7). 78% of patients lived in metropolitan areas, 85% were White, and 53% female. 44% had at least one instance of chemotherapy, surgery, or radiation treatment in 2020. In 2020, compared with patients residing in metropolitan areas, small town/rural-residing patients were less likely to use telemedicine (1.28 visits per year [95% CI, 1.27 to 1.29]
conclusionLower rural telemedicine use continued beyond the pandemic onset. Relatively lower in-person and higher ED use suggests that telemedicine expansion did not improve overall access to care for rural patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.